Meloxicam is one of the more effective and better-tolerated options for arthritis pain. It’s FDA-approved for both osteoarthritis and rheumatoid arthritis, taken as a single daily pill, and it tends to cause fewer stomach problems than older anti-inflammatory drugs like naproxen or ibuprofen. For most people with arthritis, it’s a solid choice.
How Meloxicam Works on Arthritis Pain
Meloxicam belongs to the NSAID family (the same class as ibuprofen and naproxen), but it’s not identical to those drugs. It preferentially blocks a specific enzyme called COX-2, which drives inflammation in your joints, while largely sparing COX-1, an enzyme that protects your stomach lining. This selectivity is what gives meloxicam its edge in tolerability.
By dampening COX-2 activity, meloxicam reduces the production of inflammatory chemicals called prostaglandins at the site of your joints. That translates to less swelling, less stiffness, and less pain. You may notice some relief within the first day, but the full anti-inflammatory benefit for chronic arthritis typically builds over one to two weeks of daily use.
What the Clinical Evidence Shows
In a 12-week trial of people with osteoarthritis, about 74% of patients on meloxicam achieved at least a 30% reduction in pain scores by week 12, compared with 57.5% on placebo. More impressively, roughly 58% to 60% of meloxicam patients hit the higher bar of a 50% pain reduction. That’s a meaningful difference, and these improvements showed up as early as week two.
For rheumatoid arthritis, the picture is similar. In placebo-controlled trials, meloxicam at standard doses significantly outperformed placebo across five key measures: swollen joint count, tender joint count, patient-rated pain, and both patient and physician overall assessments. In pediatric trials for juvenile arthritis, meloxicam performed comparably to naproxen, with about 69% of children meeting the standard response criteria at 12 weeks and roughly 76% showing at least 30% improvement in the number of actively inflamed joints.
Meloxicam vs. Naproxen and Ibuprofen
A six-month head-to-head trial comparing meloxicam 7.5 mg daily to naproxen 750 mg daily in rheumatoid arthritis found no significant difference in most measures of effectiveness, including pain, tender joints, and overall patient and physician assessments. Naproxen did show a slight advantage in reducing swollen joint severity, and more meloxicam patients (23.6%) dropped out for lack of effectiveness compared with naproxen patients (14.4%).
Where meloxicam clearly won was tolerability. Only 30.3% of meloxicam patients reported gastrointestinal side effects, versus 44.7% on naproxen. Half as many meloxicam patients quit the trial due to stomach problems (6% vs. 12.2%). No meloxicam patients developed ulcers during the study, while two naproxen patients did. Meloxicam patients also showed better kidney function markers and more stable hemoglobin levels over the six months.
This tradeoff is the core of why meloxicam is popular for arthritis: it’s nearly as effective as the strongest over-the-counter NSAIDs but considerably gentler on the gut. For people who need daily anti-inflammatory medication for months or years, that difference in side effects matters a lot.
Typical Dosing
The standard starting dose for both osteoarthritis and rheumatoid arthritis is 7.5 mg taken once a day. If that doesn’t provide enough relief, the dose can be increased to 15 mg once daily, which is the maximum. The once-daily dosing is a practical advantage over ibuprofen (which requires two to three doses per day) and naproxen (twice daily). It’s easier to stay consistent with a single pill.
Stomach and Heart Risks
Like all NSAIDs, meloxicam carries FDA-mandated warnings about two serious risks: cardiovascular events (heart attacks and strokes) and gastrointestinal bleeding or ulcers. These risks can occur at any time during treatment and may increase with longer use.
That said, meloxicam’s track record on stomach safety is better than most NSAIDs. In a large analysis of over 24,000 patients across 28 trials, the 7.5 mg dose carried a 0.03% risk of serious upper gastrointestinal events, significantly lower than the risk seen with diclofenac, naproxen, or piroxicam. At the higher 15 mg dose, the advantage narrowed but was still present compared with piroxicam.
For cardiovascular risk, meloxicam’s numbers were lower than diclofenac’s and similar to naproxen and piroxicam. People with existing heart disease, a history of stomach ulcers, or older age face higher risks from any NSAID, meloxicam included. It’s also contraindicated after coronary artery bypass surgery.
Who Benefits Most
Meloxicam tends to be a particularly good fit for people who need a daily anti-inflammatory but have had stomach trouble with ibuprofen or naproxen. Its once-daily dosing makes it practical for long-term use, and its COX-2 selectivity offers a real, measurable reduction in gastrointestinal side effects compared with non-selective NSAIDs.
It’s not the strongest NSAID available. If you have aggressive rheumatoid arthritis with significant joint swelling, naproxen or other medications may offer slightly better control of that specific symptom. But for the majority of people with osteoarthritis or mild to moderate rheumatoid arthritis, meloxicam provides meaningful pain relief with a favorable safety profile relative to alternatives in its class.